US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

L-Carnitine for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0057-2026
Class II · Moderate risk Ongoing

L-Arginine HCl for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0056-2026
Class II · Moderate risk Ongoing

L-Arginine for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0055-2026
Class II · Moderate risk Ongoing

Glycine for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0054-2026
Class II · Moderate risk Ongoing

GHK-Cu

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0051-2026
Class II · Moderate risk Ongoing

GAC for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0050-2026
Class II · Moderate risk Ongoing

Biotin for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0048-2026
Class II · Moderate risk Ongoing

B-Complex for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0047-2026
Class II · Moderate risk Ongoing

Ascorbic Acid

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0041-2026
Class II · Moderate risk Ongoing

Ascorbic Acid

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0040-2026
Class II · Moderate risk Ongoing

Amino Blend for Injection

Reason Lack of Assurance of Sterility

GenoGenix LLC D-0039-2026
Class II · Moderate risk Ongoing

Sucralfate Tablets

Reason CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Amerisource Health Services LLC NDC 60687-695-01 D-0598-2025
Class II · Moderate risk Ongoing

Levoxyl

Reason Subpotent drug

Pfizer NDC 60793-851-01 D-0575-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Breckenridge Pharmaceutical, Inc. NDC 82009-032-10 D-0580-2025
Class II · Moderate risk Ongoing

Doxepin Hydrochloride Capsules

Reason CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Alembic Pharmaceuticals Limited NDC 62332-637-31 D-0566-2025
Class II · Moderate risk Ongoing

BZK Antiseptic Towelette

Reason Lack of Assurance of Sterility.

Taizhou Kangping Medical Science And Technology Co., Ltd. D-0589-2025